164 related articles for article (PubMed ID: 31121982)
21. Pathophysiological significance of N-myc downstream-regulated gene 2 in cancer development through protein phosphatase 2A phosphorylation regulation.
Morishita K; Nakahata S; Ichikawa T
Cancer Sci; 2021 Jan; 112(1):22-30. PubMed ID: 33128318
[TBL] [Abstract][Full Text] [Related]
22. Acute promyelocytic leukemia drug - arsenic trioxide in the presence of eugenol shows differential action on leukemia cells (HL-60) and cardiomyocytes (H9c2) - inference from NMR study.
Binu P; Soman R; Zakhariah Hisham O; Narayanan SP; Nair RH
Toxicol Mech Methods; 2021 Jul; 31(6):457-466. PubMed ID: 33879037
[TBL] [Abstract][Full Text] [Related]
23. Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
Khaleghian A; Ghaffari SH; Ahmadian S; Alimoghaddam K; Ghavamzadeh A
J Cell Biochem; 2014 Oct; 115(10):1729-39. PubMed ID: 24819152
[TBL] [Abstract][Full Text] [Related]
24. MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.
Lu JW; Lin YM; Lai YL; Chen CY; Hu CY; Tien HF; Ou DL; Lin LI
Med Oncol; 2015 Jul; 32(7):206. PubMed ID: 26087957
[TBL] [Abstract][Full Text] [Related]
25. Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis.
Elgendy M; Cirò M; Hosseini A; Weiszmann J; Mazzarella L; Ferrari E; Cazzoli R; Curigliano G; DeCensi A; Bonanni B; Budillon A; Pelicci PG; Janssens V; Ogris M; Baccarini M; Lanfrancone L; Weckwerth W; Foiani M; Minucci S
Cancer Cell; 2019 May; 35(5):798-815.e5. PubMed ID: 31031016
[TBL] [Abstract][Full Text] [Related]
26. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
27. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
Kinjo K; Kizaki M; Muto A; Fukuchi Y; Umezawa A; Yamato K; Nishihara T; Hata J; Ito M; Ueyama Y; Ikeda Y
Leukemia; 2000 Mar; 14(3):431-8. PubMed ID: 10720138
[TBL] [Abstract][Full Text] [Related]
28. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells.
Park JW; Choi YJ; Jang MA; Baek SH; Lim JH; Passaniti T; Kwon TK
Biochem Biophys Res Commun; 2001 Aug; 286(4):726-34. PubMed ID: 11520058
[TBL] [Abstract][Full Text] [Related]
29. In vitro exposure of acute promyelocytic leukemia cells to arsenic trioxide (As2O3) induces the solitary expression of CD66c (NCA-50/90), a member of the CEA family.
Di Noto R; Boccuni P; Costantini S; Dello Russo A; Lo Pardo C; Copia C; Annunziata M; Cimino R; Ferrara F; Del Vecchio L
Tissue Antigens; 1999 Dec; 54(6):597-602. PubMed ID: 10674975
[TBL] [Abstract][Full Text] [Related]
30. Catalase activity and arsenic sensitivity in acute leukemia.
Coe E; Schimmer AD
Leuk Lymphoma; 2008 Oct; 49(10):1976-81. PubMed ID: 18949620
[TBL] [Abstract][Full Text] [Related]
31. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
Shao W; Fanelli M; Ferrara FF; Riccioni R; Rosenauer A; Davison K; Lamph WW; Waxman S; Pelicci PG; Lo Coco F; Avvisati G; Testa U; Peschle C; Gambacorti-Passerini C; Nervi C; Miller WH
J Natl Cancer Inst; 1998 Jan; 90(2):124-33. PubMed ID: 9450572
[TBL] [Abstract][Full Text] [Related]
32. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
Zhu XH; Shen YL; Jing YK; Cai X; Jia PM; Huang Y; Tang W; Shi GY; Sun YP; Dai J; Wang ZY; Chen SJ; Zhang TD; Waxman S; Chen Z; Chen GQ
J Natl Cancer Inst; 1999 May; 91(9):772-8. PubMed ID: 10328107
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of protein phosphatase 2A (PP2A) prevents Mcl-1 protein dephosphorylation at the Thr-163/Ser-159 phosphodegron, dramatically reducing expression in Mcl-1-amplified lymphoma cells.
Nifoussi SK; Ratcliffe NR; Ornstein DL; Kasof G; Strack S; Craig RW
J Biol Chem; 2014 Aug; 289(32):21950-9. PubMed ID: 24939844
[TBL] [Abstract][Full Text] [Related]
34. PP2A-Mediated GSK3β Dephosphorylation Is Required for Protocadherin-7-Dependent Regulation of Small GTPase RhoA in Osteoclasts.
Kim H; Takegahara N; Choi Y
Cells; 2023 Jul; 12(15):. PubMed ID: 37566044
[TBL] [Abstract][Full Text] [Related]
35. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
[TBL] [Abstract][Full Text] [Related]
36. Arsenic trioxide: acute promyelocytic leukemia and beyond.
Bachleitner-Hofmann T; Kees M; Gisslinger H
Leuk Lymphoma; 2002 Aug; 43(8):1535-40. PubMed ID: 12400595
[TBL] [Abstract][Full Text] [Related]
37. As2O3 enhances the anion transport activity of band 3 and the action is related with the C-terminal 16 residues of the protein.
Fu GH; Wang Y; Xi YH; Guo ZW; Liu XB; Bai SZ; Yang BF; Chen GQ
J Drug Target; 2005 May; 13(4):235-43. PubMed ID: 16051535
[TBL] [Abstract][Full Text] [Related]
38. A New alpha5beta1 integrin-dependent survival pathway through GSK3beta activation in leukemic cells.
De Toni-Costes F; Despeaux M; Bertrand J; Bourogaa E; Ysebaert L; Payrastre B; Racaud-Sultan C
PLoS One; 2010 Mar; 5(3):e9807. PubMed ID: 20352103
[TBL] [Abstract][Full Text] [Related]
39. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside.
Rojewski MT; Körper S; Schrezenmeier H
Leuk Lymphoma; 2004 Dec; 45(12):2387-401. PubMed ID: 15621751
[TBL] [Abstract][Full Text] [Related]
40. Arsenic trioxide and promyelocytic leukemia protein-adenovirus synergistically inhibit in vitro and in vivo growth of a hepatoma cell line.
Cui L; Zhang S; Zhang W; Hu Z; Cao Z; Li T
Oncol Res; 2010; 18(7):305-14. PubMed ID: 20377131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
